We provide trade recommendation to complement the latest
expert consensus on AC Immune SA. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at this moment. AC Immune dividends can provide a clue to the current value of the stock. The firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include AC Immune income statement, its balance sheet, and the statement of cash flows. Potential AC Immune investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AC Immune investors may use each financial statement separately, they are all related. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AC Immune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of AC Immune
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of AC Immune performance into the future periods or doing a reasonable stock valuation. The intrinsic value of AC Immune shares is the value that is considered the true value of the share. If
the intrinsic value of ACIU is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares AC Immune. Please read more on our
fundamental analysis page.
How effective is AC Immune in utilizing its assets?
AC Immune reports assets on its Balance Sheet. It represents the amount of ACIU resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, AC Immune aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect ACIU volatility, please check the breakdown of all its
fundamentals.
Are AC Immune Earnings Expected to grow?
The
future earnings power of AC Immune involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of AC Immune factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. AC Immune
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of ACIU
expected earnings.
AC Immune Gross Profit
AC Immune Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing AC Immune previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show AC Immune Gross Profit growth over the last 10 years. Please check AC Immune's
gross profit and other
fundamental indicators for more details.
Breaking down the case for AC Immune
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of AC Immune is not uncomon. Many companies such as AC Immune have both institutions investors and insiders sharing the ownership. Retail investors typically buy and sell stocks in round lots of 100 shares or more. Other other hand institutional investors are known to buy and sell in block trades of 10,000 shares or more. Let's take a look at how the ownership of AC Immune is distributed among investors.
Ownership Allocation
AC Immune SA secures a total of seventy-one million eight hundred sixty thousand
outstanding shares. AC Immune SA shows tangible amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
| Retail Investors25.32% | Insiders47.9% | Institutions26.78% |
| Retail Investors | 25.32 |
| Insiders | 47.9 |
| Institutions | 26.78 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AC Immune has an asset utilization ratio of 13.92 percent. This implies that the company is making $0.14 for each dollar of assets. An increasing asset utilization means that AC Immune SA is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 238.92 Million | 97.16 |
| Assets Non Current | 6.99 Million | 2.84 |
Will AC Immune spontaneously start a bounce back?
AC Immune newest variance boosts over 18.99. As of the 2nd of August, AC Immune owns the Standard Deviation of 4.36,
coefficient of variation of
(4,964), and Market Risk Adjusted Performance of 0.3318. AC Immune SA
technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Strictly speaking, you can use this information to find out if the entity will indeed mirror its model of
historical prices and volume patterns, or the prices will eventually revert. We have collected data for nineteen
technical drivers for AC Immune, which can be compared to its peers in the sector. Please confirm
AC Immune SA coefficient of variation, as well as the
relationship between the treynor ratio and
semi variance to decide if AC Immune SA is priced fairly, providing market reflects its prevailing price of 6.53 per share. Given that AC Immune SA has
jensen alpha of
(0.046052), we suggest you to validate AC Immune's latest market performance to make sure the company can sustain itself sooner or later.
Our Takeaway on AC Immune Investment
Whereas many of the other players in the biotechnology industry are either recovering or due for a correction, AC Immune may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current AC Immune valuation and our trade advice on AC Immune is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AC Immune.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of AC Immune. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com